

Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca-2 and PANC-1 cells

JI HE¹, PIYUSH BUGDE¹, JIAWEI LI¹, RIYA BISWAS¹, SITING LI^{1,2},
XUEWEI YANG², FANG TIAN³, ZIMEI WU⁴ and YAN LI¹

¹Department of Biomedicine and Medical Diagnostics, School of Science, Auckland University of Technology, Auckland 1010, New Zealand; ²Guangdong Key Laboratory of Plant Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060; ³Nycrist Pharmatech Limited, Shenzhen 518107, P.R. China; ⁴School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand

Received August 8, 2023; Accepted November 1, 2023

DOI: 10.3892/or.2023.8666

Abstract. Gemcitabine-based chemotherapy has been widely adopted as the standard and preferred chemotherapy regimen for treating advanced pancreatic cancer. However, the contribution of multidrug resistance protein 5 (MRP5) to gemcitabine resistance and pancreatic cancer progression remains controversial. In the present study, the effect of silencing MRP5 on gemcitabine resistance and cell proliferation and migration of human pancreatic cancer MIA Paca-2 and PANC-1 cells was investigated by using short-hairpin RNA delivered by lentiviral vector transduction. The knockdown of MRP5 was confirmed on both mRNA and protein levels using qPCR and surface staining assays, respectively. MRP5-regulated gemcitabine sensitivity was assessed by MTT, PrestoBlue and apoptosis assays. The effect of MRP5 on pancreatic cancer cell proliferation and migration was determined using colony-formation, wound-healing and Transwell migration assays. The interaction of gemcitabine and cyclic guanosine monophosphate (cGMP) with MRP5 protein was explored using molecular docking. The results indicated that the *MRP5* mRNA and protein levels were significantly reduced in all the MIA Paca-2 and PANC-1 clones. MRP5 affected gemcitabine cytotoxicity and the rate of gemcitabine-induced apoptosis. Silencing MRP5 decreased cell proliferation and migration in both MIA Paca-2 and PANC-1 cells. Docking studies showed high binding affinity of cGMP towards MRP5, indicating the potential of MRP5-mediated cGMP accumulation in the microenvironment. In conclusion, MRP5 has an important role

in cancer proliferation and migration in addition to its drug efflux functions in two widely available pancreatic tumour cell lines (MIA Paca-2 and PANC-1).

Introduction

Pancreatic cancer is one of the leading causes of cancer-related death worldwide; it is an aggressive disease that is usually advanced at the time of diagnosis. Despite all of the developments in pancreatic cancer research, the death to incidence ratio has not significantly improved in the last couple of decades (1-3). Pancreatic malignancy has a 5-year survival rate of 8% for all stages (4). The disease advances asymptotically in 80% of patients and is generally discovered in the later stages, by which time the only treatment option is chemotherapy, and its surgical removal is not possible (5). Even after chemotherapy, the chances of survival are not significantly high due to multidrug resistance (MDR), which impairs the efficacy of the combination chemotherapy (5). Various genetic mutations associated with pancreatic ductal adenocarcinoma (PDAC) and dysregulation of several signalling pathways make PDAC highly heterogeneous (6). Since 1997 to up until now, gemcitabine (a cyclic nucleotide) has been used as the first-line treatment drug for PDAC (6). While gemcitabine has marginally improved the patients' survival rate, the overall survival of patients with advanced disease remains below six months. Due to the low efficacy of gemcitabine, efforts are being made to increase the survival of the patients (6). MDR is an intricate process and there are a number of factors working in parallel, which may influence the process, e.g., insufficient drug delivery due to a high level of fibrosis and low vascularity, accelerated drug metabolism and DNA repair, blocking of apoptotic pathways, metabolic changes and the presence of highly resistant stem-like cells (7-10). Although accumulating preclinical evidence indicates that ATP-binding cassette (ABC) transporter-mediated drug efflux contributes to MDR (11,12), the lack of success of ABC transporter inhibitor in clinical trials suggests our knowledge in this area is still limited or biased (13).

Correspondence to: Dr Yan Li, Department of Biomedicine and Medical Diagnostics, School of Science, Auckland University of Technology, 34 St. Paul Street, Auckland 1010, New Zealand
E-mail: yan.li@aut.ac.nz

Key words: ABC transporters, pancreatic cancer, multidrug resistance, MRP5, gemcitabine

ABC transporters belong to a highly conserved family of proteins, and to date, 48 genes and one pseudogene have been identified in humans (12,14-16). The family is further subdivided into seven subfamilies (ABCA-G) based on the premise of their structure and sequence (16-18). ABC transporters are transmembrane proteins, and as the name suggests, ABC transporters utilise energy from ATP hydrolysis for the efflux of their substrates (4,17,19). Overexpression of one of the ABC transporter subfamilies was found in PDAC (20-22). The existence of ABC transporter expression signatures in PDAC and their association with clinicopathological characteristics of the tumours has been studied by Mohelnikova-Duchonova *et al.* (23) and dysregulation of the expression of several members of the ABC family has been observed. Upregulation of ABCB4, ABCB11, ABCC1, ABCC3, ABCC5 [aka., multidrug resistance protein 5 (MRP5)], ABCC10 and ABCG2 has been noted in PDAC, compared to nonneoplastic tissues (4-6,24).

MRPs are integral membrane proteins mediating the ATP-dependent export of organic anions out of cells. Previously, it has been observed that MRP4 and MRP5 were localised in duct cells, acinar cells and pancreatic cancer cells (22,25). The MRP5 mRNA level was significantly higher in pancreatic carcinoma tissue compared to normal pancreatic tissue (6,11,17,26). The MRP5 A-2G AA genotype also showed a significant association with overall survival in patients with pancreatic cancer (27). MRP5 has also been demonstrated to confer gemcitabine resistance in various *in vitro* cell culture models (5,6,17,26,28,29).

Apart from their drug efflux abilities, emerging evidence suggests the contributions of ABC transporters to cancer biology in either a substrate efflux-dependent or -independent manner (12,30-32), leading to cancer cell proliferation, differentiation, invasion and/or migration. Thus, gaining better insight into the role of ABC transporters in both cancer biology and tumour resistance may lead to new and better anti-cancer strategies. In the present study, it was hypothesised that MRP5 transporter possibly has pleiotropic roles in cancer development, in addition to its gemcitabine efflux actions in pancreatic cancer cells (16). The role of MRP5 in cancer hallmarks of pancreatic cancer cells was investigated by using lentiviral short-hairpin (sh)RNA gene modulation techniques. Stable knockdown of the MRP5 gene was achieved and its effects on MRP5 expression, gemcitabine cytotoxicity and growth and migration of pancreatic cancer cells were measured.

Materials and methods

Cell culture. The human pancreatic cancer cell lines MIA Paca-2 and PANC-1 were obtained from the American Type Culture Collection. MIA Paca-2 and PANC-1 cell lines were cultured using complete DMEM (cat. no. 11965-092; Thermo Fisher Scientific, Inc.) supplemented with 10% (v/v) FBS (cat. no. MG-FBS0820; MediRay) and 2 mmol/l L-glutamine (cat. no. 20530081; Thermo Fisher Scientific, Inc.) in a humidified atmosphere with 5% carbon dioxide at 37°C.

Lentiviral transduction. Cells were seeded at a density of 1.2×10^4 cells per well in a 96-well plate and incubated for 24 h. The culture medium was then replaced with 110 μ l fresh

medium containing hexadimethrine bromide (final concentration, 8 μ g/ml) (cat. no. H9268; Sigma-Aldrich; Merck KGaA). An aliquot of 1 μ l custom-designed shRNA lentiviral particles (Sigma-Aldrich; Merck KGaA) targeting the *MRP5* gene was added to MIA Paca-2 and PANC-1 cells (multiplicity of infection, 2) and incubated for 20 h. MISSION® Non-mammalian shRNA control transduction particles (cat. no. SHC002V; Sigma-Aldrich; Merck KGaA) were used as a negative control. After a 20-h incubation, the pooled population was transferred to two 75 mm Petri Dishes and the transduced cells were selected in medium containing 0.4 μ g/ml puromycin (cat. no. A1113803; Thermo Fisher Scientific, Inc.). For further investigation, two clones of each cell type were randomly picked up, which were MIA Paca-2 clones 1 (M c1) and 2 (M c2) and PANC-1 clones 1 (P c1) and 2 (P c2). The shRNA target sequence is 5'-CCACATCTTCAATAGTGCTAT-3'. The sequence is unique in the human transcriptome, which only targets *MRP5* mRNA and its variants. The insert sequence of the scrambled control is 5'-CCGGCAACAAGATGAAGAGCACCAACTC-GAGTTGGTGTCTTTCATCTTGTGTTT-3'.

RNA extraction and reverse transcription-quantitative (RT-q) PCR. RNA extraction from cultured cells was carried out using TRIzol® reagent (cat. no. 15596018; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The total RNA was quantified using a NanoDrop® ND-1000 UV spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc.). Primer sequences as listed in Table I (33,34) and were purchased from Integrated DNA Technologies, Inc. RT-qPCR amplification and analysis were performed with a Light Cycler 480 Instrument (Roche Diagnostics) using the LightCycler® EvoScript RNA SYBR® Green I Master one-step RT-qPCR kit (cat. no. 07800134001; Roche Applied Science). For each reaction, an aliquot of 5 μ l RNA sample (10 ng) was mixed with 1 μ l primer mix (final concentration 0.4 μ M), 4 μ l master mix (5x conc.) and 10 μ l PCR grade water. The reaction conditions of RT-qPCR were 60°C for 15 min (reverse transcription) and 95°C for 10 min (enzyme activation), followed by 45 cycles of 95°C for 10 sec (denaturation) and 59°C for 30 sec (annealing and extension). *MRP5* mRNA expression in each sample was normalised to the reference gene GAPDH and the results were analysed using the comparative threshold cycle method (35).

MRP5 surface staining. MRP5 expression was confirmed by surface immunostaining of the protein. Cells were harvested and aliquoted at 1×10^6 cells into Eppendorf tubes. After fixation in 1% paraformaldehyde (PFA) (cat. no. P6148; Sigma-Aldrich; Merck KGaA) at 4°C for 15 min, the cells underwent permeabilization in 0.2% saponin (cat. no. 47036-50G-F, Sigma-Aldrich; Merck KGaA) at 4°C for 15 min, blocking in 5% bovine serum albumin (BSA) (cat. no. NZ21-69100-038; pH Scientific) at room temperature for 15 min, and staining with anti-MRP5 rat monoclonal antibody (M5II-54) (1:20 in 2% BSA; cat. no. MA1-35684; Thermo Fisher Scientific, Inc.) or Rat IgG2 α Isotype Control primary antibody (1:20 in 2% BSA; cat. no. 02-9688, Thermo Fisher Scientific, Inc.) at 4°C for 1 h. The cells were then stained with goat anti-Rat IgG H&L (Alexa Fluor® 488) secondary antibody (1:200 in 2% BSA;

Table I. Primers used for PCR (5'-3').

Target gene	Forward	Reverse	(Refs.)
<i>MRP5</i>	AGAGGTGACCTTTGAGAACGCA	CTCCAGATAACTCCACCAGACGG	(34)
<i>GAPDH</i>	GCACCGTCAAGGCTGAGAAC	GCCTTCTCCATGGTGGTGAA	(35)

MRP5, multidrug resistance protein 5.

cat. no. ab96887; Abcam) at 4°C for 1 h. The cells were washed three times with PBS containing 0.1% NaN₃ and 0.1% saponin between each step. After secondary antibody incubation, the cells were then washed and resuspended in 500 µl 1% PFA. Fluorescence was detected at 488 nm excitation and 525 nm emission wavelength using a flow cytometer (MoFlo XDP; Beckman Coulter, Inc.). The mean fluorescence intensity was determined using Kaluza Flow cytometry software version 2.2.1 (Beckman Coulter, Inc.).

MRP5 substrate accumulation. Steady-state cellular accumulation of an MRP5 substrate, 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) (cat. no. B8806; Thermo Fisher Scientific, Inc.) was determined using a flow cytometer (MoFlo XDP; Beckman Coulter, Inc.). An MRP5 inhibitor, benzbromarone (cat. no. B5774; Sigma-Aldrich; Merck KGaA), was used as a positive control to validate the function of MRP5. MIA Paca-2 and PANC-1 cells were washed with FBS- and phenol red-free DMEM (cat. no. 31053028; Thermo Fisher Scientific, Inc.) and were resuspended in the same medium to achieve a density of 0.5x10⁶ cells/ml. The accumulation of BCECF was performed by incubating 1 ml cell suspension with benzbromarone (50 µM) or the vehicle (0.1% DMSO) at 37°C for 30 min, followed by incubation with 0.25 µM BCECF-AM at 37°C for 15 min. The accumulation was terminated by adding ice-cold PBS. The cells were then washed with ice-cold PBS and resuspended in 500 µl 1% PFA. The samples were analysed with a standard laser for excitation at 488 nm and a bandpass filter at 525 nm to detect fluorescence. The mean fluorescence intensity was determined using Kaluza Flow cytometry software version 2.2.1 (Beckman Coulter, Inc.).

Cytotoxicity assay. The gemcitabine-induced growth inhibition was first determined in 2D-cultured pancreatic cancer cells using MTT assay. Cells were seeded at a density of 5,000 cells per well in 96-well plates and incubated for 24 h to allow cells to attach to the well surface. After incubation, cells were treated with gemcitabine (cat. no. G6423; Sigma-Aldrich; Merck KGaA) at various concentrations for 72 h. Gemcitabine stock solution at a concentration of 50 mM was prepared by dissolving gemcitabine powder in Milli-Q water. After treatment, the drug solution from each well was replaced with fresh complete medium, followed by the addition of 10 µl 12 mM MTT (cat. no. M2128; Sigma-Aldrich; Merck KGaA) stock solution. The cells were then incubated for 4 h at 37°C before adding 150 µl DMSO to each well. The cell viability was quantified by measuring the absorbance at 570 nm normalised to the mean absorbance of vehicle control. The IC₅₀ values

for gemcitabine-induced growth inhibition were determined using nonlinear regression in PRISM® software (version 8.0; GraphPad; Dotmatics).

For 3D culture models, MIA Paca-2 and PANC-1 clones were allowed to grow in 96-well low-adhesion plates (cat. no. CLS7007; Sigma-Aldrich; Merck KGaA) for 10 days, followed by 72-h incubation with different concentrations of gemcitabine. After incubation, the drug-containing medium was removed and the cells were stained with 100 µl 1X PrestoBlue (cat. no. A13261; Thermo Fisher Scientific, Inc.) at 37°C for 1 h and the fluorescence was determined at an excitation of 560 nm/emission of 590 nm using a SPARK® Microplate Spectrofluorometer (Molecular Devices, LLC).

In another experiment, the cytotoxicity of gemcitabine was assessed using a 2D colony formation assay. Cells were seeded in 96-well plates at a density of 1,000 cells per well. After 1 day, cells were treated with 2.5, 5 and 10 nM gemcitabine for 3 days, followed by incubation with drug-free medium for 7 days. The medium was changed every 3 days. After incubation, cells were fixed with 4% PFA for 15 min and stained with 0.5% crystal violet (cat. no. C6158; Sigma-Aldrich; Merck KGaA) for 15 min at room temperature. The stained cells were washed with tap water and air-dried for a few mins before being analysed under a microscope.

Apoptosis assay. Cells were seeded at a density of 5,000 cells per well in 96-well plates. After overnight incubation at 37°C and 5% CO₂, MIA Paca-2 and PANC-1 cells were treated with different concentrations of gemcitabine for 24 and 48 h, respectively. To terminate the drug exposure, the drug-containing medium was replaced with 100 µl of diluted CellEvent™ Caspase-3/7 detection reagents (final concentration 2 µM) (cat. no. C10427; Thermo Fisher Scientific, Inc.) and cells were then incubated for 60 min at 37°C. The fluorescence was measured at an excitation of 467 nm/emission of 539 nm on a SPARK® Microplate Spectrofluorometer (Molecular Devices, LLC). Images were also acquired with a Leica DMI8 inverted fluorescence microscope (Leica Microsystems, GmbH).

Colony-formation assay. Cells were seeded in 6-well plates at a density of 200 cells per well, followed by a 10-day incubation at 37°C and 5% CO₂. The medium was changed every 3 days. After incubation, cells were fixed with 4% PFA for 15 min and stained with 0.5% crystal violet for 15 min at room temperature. The stained cells were washed with tap water and air-dried for a few mins before being analysed under an inverted microscope (Zeiss AG). Colonies of >50 cells were scored for survival and counted using ImageJ 1.52g software (National Institutes of Health).

Wound-healing assay. Cells in complete DMEM were seeded into 6-well plates at a density of 3×10^5 cells per well and allowed to grow until a confluent cell layer was obtained. A linear scratch was made in the plate using a sterile 200 μ l pipette tip (cat. no. 1030-260-000-9; Thermo Fisher Scientific, Inc.). Cells were washed and then incubated with DMEM supplemented with 0.5% FBS to prevent apoptosis (36). Images were acquired at 0, 24, 48 and 72 h for MIA Paca-2 cells and 0, 16, 24 and 40 h for PANC-1 cells with a Leica DMi8 inverted fluorescence microscope (Leica Microsystems GmbH). Cell migration was analysed using ImageJ 1.52g software.

Transwell migration assay. Cells in serum-free DMEM were seeded in the Corning® Costar® Transwell® cell culture inserts (cat. no. CLS3464; Sigma-Aldrich; Merck KGaA) at a density of 3×10^5 cells per insert. The inserts were placed in 12-well plates and the bottom wells were filled with 1 ml complete medium. The cells were incubated at 37°C and 5% CO₂ for 48 h. After this incubation, the non-migrated cells on the upper side of the membrane were removed using a cotton swab. The migrated cells on the lower side of the membrane were fixed with 4% PFA and stained with 0.1% crystal violet in 2% ethanol. Images were taken with a Leica DMi8 inverted fluorescence microscope (Leica Microsystems GmbH) and analysed using ImageJ 1.52g software.

In silico analysis. The main software and tools used for molecular docking studies were AlphaFold (<https://alphafold.ebi.ac.uk/>) (37,38), PubChem (<https://pubchem.ncbi.nlm.nih.gov/>), Openbabel (39), AutoDock 4.2 (40), Protein-Ligand Interaction Profiler (<https://plip-tool.biotec.tu-dresden.de/>) (41), ProteinsPlus (<https://proteins.plus/>) (40,42) and LigPlot (43). The ligands were downloaded from PubChem in SDF format. The protein structure of MRP5 was downloaded from AlphaFold. The ligands in SDF file format were converted to pdb format using Openbabel. All of the ligands were docked with their receptor molecule using AutoDock 4.2. Results were evaluated and visualised using Protein-Ligand Interaction Profiler, ProteinsPlus and LigPlot.

Statistical analysis. Data were presented by descriptive statistics as the mean \pm standard deviation. Linear and non-linear regression were carried out using PRISM® software (version 8.0; GraphPad; Dotmatics). The statistical analysis was performed by a one-way analysis of variance (ANOVA) with a Dunnett's post-hoc test or a two-way ANOVA with Sidak's post-hoc test. All data analysed using ANOVAs should meet the assumptions of equal variance and homogeneity. $P < 0.05$ was considered to indicate statistical significance.

Results

MIA Paca-2 and PANC-1 cells endogenously express high MRP5. High MRP5 mRNA expression was observed in PANC-1 (ranked 7/23) and MIA PaCa-2 (ranked 11/32) cells compared to other pancreatic cancer cell lines based on the Wagner dataset stored in ONCOMINE (<https://www.oncomine.org>) (Fig. 1A). The surface protein expression of MRP5 on pancreatic cancer cells was assessed by staining with anti-MRP5 primary and control isotype IgG2a antibody.

Fig. 1B and C show increased fluorescence staining with the MRP5 antibody (red colour) on MIA Paca-2 and PANC-1 cells (~three-fold) compared to the isotype control antibody (green colour), suggesting the expression of MRP5 protein on the surface of pancreatic cancer cells. Furthermore, the MRP5 efflux activity in MIA Paca-2 and PANC-1 cells was investigated by determining the cellular accumulation of a model MRP5 substrate, BCECF, in the presence or absence of MRP inhibitor benzbromarone at designated time-points. Benzbromarone significantly ($P < 0.0001$) increased the steady-state accumulation of BCECF in both MIA Paca-2 and PANC-1 cells (Fig. 1D). Taken together, these results indicated that MIA Paca-2 and PANC-1 cells have high endogenous expression of MRP5.

Reduced MRP5 expression in MRP5-knockdown clones. Significant reduction in the MRP5 mRNA expression was seen for all knockdown clones transduced with shRNA lentiviral particles. In MIA PaCa-2 cells, the mRNA transcripts of the MRP5 gene were significantly decreased by 37% ($P < 0.001$) and 43% ($P < 0.0001$) in M c1 and M c2 compared to the scramble control, respectively (Fig. 2A). A similar trend was seen in PANC-1 cells, as P c1 and P c2 showed a significant ($P < 0.001$) reduction in MRP5 mRNA levels by 38 and 46% compared to the scrambled control, respectively (Fig. 2B).

MRP5 gene knockdown clones were further confirmed at the protein level by cell surface staining. The mean fluorescence intensity that indicates the MRP5 surface expression was decreased by 17 and 22% for M c1 ($P < 0.05$) and M c2 ($P < 0.05$) and by 28 and 51% for P c1 ($P < 0.05$) and P c2 ($P < 0.01$) compared to the scrambled control, respectively (Fig. 2C-F). These results suggested that transduction of shRNA lentiviral particles results in a significant decrease of the MRP5 mRNA and surface protein expression of both MIA PaCa-2 and PANC-1 cells.

The integration of plasmid and the potential off-target effects of MRP5-short-hairpin RNA were examined in MRP5 knockdown cells (Fig. S1). No significant differences of ABCB1 and ABCC2 mRNA expression were found in MRP5 knockdown cells compared to scramble control. However, the accumulation of BCECF remained at the same level between MRP5 knockdown cells and scramble control for both MIA Paca-2 and PANC-1 cells (Fig. S2). This may be caused by either single-cell variability or the loss of substrate specificity in the models used in the present study.

MRP5 knockdown sensitises pancreatic cancer cells to gemcitabine growth inhibition. MIA PaCa-2 and PANC-1 clones were treated with 0-150 and 0-1,500 nM gemcitabine, respectively, in the 2D culture models. The 72-h cytotoxicity of gemcitabine was determined using an MTT assay. Gemcitabine inhibited the proliferation of scrambled control and knockdown clones in a dose-dependent manner. Table II shows that the IC₅₀ values were decreased by 52% (M c1) and 42% (M c2) for MIA PaCa-2 cells (Fig. 3A) and by 46% (P c1) and 41% (P c2) for PANC-1 cells (Fig. 3B) compared to the scrambled control, respectively. Similar patterns were observed in pancreatic cancer cells by using colony formation assays (Fig. S3). The response of the two pancreatic cancer cell lines to gemcitabine was also examined in an *in vitro* 3D cell culture model. Gemcitabine was more potent against control




Figure 1. Functional overexpression of MRP5 in human pancreatic cancer MIA PaCa-2 and PANC-1 cells. (A) High *MRP5* mRNA expression in both MIA PaCa-2 and PANC-1 cells (in red colour) compared to other pancreatic cancer cell lines from the Wagner dataset stored in ONCOMINE (<https://www.onco-mine.org>). (B and C) MRP5 protein detected in representative flow cytometry histogram of cell surface staining using the anti-MRP5 primary antibody (red) and isotype control IgG2a (green) on (B) MIA PaCa-2 and (C) PANC-1 cells. Both the primary antibody and isotype control were labelled with Alexa Fluor 488 secondary antibody. The x-axis is the fluorescence signal intensity displayed in a linear log scale. (D) Functional expression of MRP5 detected by BCECF accumulation in MIA PaCa-2 and PANC-1 cells at 15 min in the presence and absence of 50 μ M benzobromarone. All data are normalised to the fluorescence intensity determined in the absence of benzobromarone. The bars represent the mean and standard deviation from three independent experiments performed in triplicates. **** $P < 0.0001$ according to Sidak's post-hoc test that followed two-way ANOVA. MRP5, multidrug resistance protein 5.

pancreatic cancer cells (IC_{50} values of 17.26 and 13.88 nM for Mia PaCa-2 and PANC-1 cells, respectively) grown in 2D cultures in comparison with those in 3D cultures (both IC_{50} values $>100 \mu$ M). Silencing *MRP5* led to markedly increased sensitivity to gemcitabine in 3D culture models of both Mia PaCa-2 and PANC-1 compared to the control (Fig. 3C and D). In contrast, the knockdown clones and scramble control for both MIA PaCa-2 and PANC-1 cells showed the same vulnerability to a poly (ADP-ribose) polymerase inhibitor olaparib, which is not an MRP5 substrate (Fig. S4 and Table SI).

MRP5 knockdown increases the gemcitabine-induced apoptosis rate. Gemcitabine-induced apoptosis was measured by detecting caspase activity in the apoptotic population. The time course was determined based on the cell type. MIA PaCa-2 clones exposed to gemcitabine exhibited extensive apoptosis after a 24-h incubation. PANC-1 clones showed minor apoptosis after 24 h of treatment; thus, the incubation time was increased to 48 h. In MIA PaCa-2 clones M c1 and M c2 treated with 100 nM gemcitabine, the apoptotic population increased by $67.50 \pm 16.40\%$ ($P < 0.01$) and $44.99 \pm 5.21\%$ ($P < 0.01$) compared to the scrambled control, respectively (Fig. 4A and B). After treatment with 200 nM gemcitabine, the apoptotic population increased by $53.15 \pm 32.50\%$ ($P < 0.05$) and $34.34 \pm 5.00\%$ ($P < 0.05$) for M c1 and M c2, respectively (Fig. 4A and B).

A similar trend was seen in PANC-1 cells-after treatment with 100 nM gemcitabine, the apoptotic population increased by 55.21 ± 18.25 and $65.35 \pm 37.47\%$ for P c1 ($P < 0.05$) and P c2 ($P < 0.001$), respectively (Fig. 4C and D). In PANC-1 cells treated with 200 nM gemcitabine, the apoptotic population increased by 97.18 ± 23.44 and $49.09 \pm 20.94\%$ for P c1 ($P < 0.05$) and P c2 ($P < 0.05$), respectively (Fig. 4C and D). These results signified increased gemcitabine sensitivity in ABCC5 knockdown pancreatic cancer cells.

MRP5 knockdown suppresses cell proliferation and migration.

The effect of MRP5 on pancreatic cancer clonogenic capacity was examined using a colony-formation assay. Silencing of *MRP5* decreased the clonogenic capacity of Mia PaCa-2 and PANC-1 cells (Fig. 5). The colonies formed within 10 days of incubation for the control Mia PaCa-2 and PANC-1 cells were significantly more numerous than those of the *MRP5* knockdown cells.

Silencing *MRP5* decreased wound-induced migration in Mia PaCa-2 and PANC-1 cells (Fig. 6). Complete wound healing occurred within 72 and 40 h for the control Mia PaCa-2 and PANC-1 cells, respectively; but not in the *MRP5* knockdown cell lines (Fig. 6A and B).

Silencing of *MRP5* decreased cell migration in the Transwell assays quantifying cell migration toward the




Figure 2. *MRP5* expression at the mRNA level in (A) MIA Paca-2 and (B) PANC-1 clones transduced with scrambled control and multidrug resistance protein 5-short-hairpin RNA. Relative *MRP5* mRNA expression was detected by reverse transcription-quantitative PCR. *MRP5* mRNA expression was normalised to the reference gene GAPDH and relative quantitation of gene expression was calculated using the comparative threshold cycle method ($2^{-\Delta\Delta C_t}$). All data were expressed as the mean and standard deviation from three independent experiments performed in duplicates. Cell surface protein expression of *MRP5* in (C) MIA Paca-2 and (D) PANC-1 cells presented as the mean percentage of the scrambled control. The bar represents the mean and standard deviation from three independent experiments performed in triplicates. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$ from Dunnett's post-hoc test that followed one-way ANOVA for comparison of all *MRP5* knockdown clones to the scrambled control. (E and F) *MRP5* protein detected in representative flow cytometry histograms of cell surface staining using anti-*MRP5* primary antibody and Alexa Fluor 488 secondary antibody on (E) MIA Paca-2 and (F) PANC-1 clones. The x-axis is the fluorescence signal intensity displayed in a linear log scale. *MRP5*, multidrug resistance protein 5; shRNA, short-hairpin RNA.

complete medium for 48 h (Fig. 7). The migrated cells per field were reduced by >50% for both cell lines examined.

Docking studies using AutoDock 4.2. In the present study, gemcitabine and cGMP were analysed through a molecular docking study using AutoDock 4.2 software. Docking results against receptor molecules obtained from Protein-Ligand Interaction Profiler showed that both gemcitabine and cGMP formed four hydrogen bonds with ABCC5. The estimated free energy of binding of gemcitabine and cGMP were determined to be -2.77 and -6.44 kcal/mol, respectively (Fig. 8).

Discussion

Based on robust evidence from multiple randomised controlled trials, gemcitabine and its combination regimens are clinically important for the treatment of pancreatic cancers. Although various patients benefit from gemcitabine-based treatment, certain patients fail to respond to treatment. There is an urgent need for developing strategies to overcome gemcitabine-based chemoresistance and improve the survival rate and life expectancy in the patients. Numerous factors are involved in the MDR of pancreatic cancer and one of the common factors




Figure 3. Representative gemcitabine-induced inhibition of growth of MIA Paca-2 and PANC-1 clones transduced with scrambled control and multidrug resistance protein 5-short-hairpin RNA in 2D and 3D culture models. (A) IC₅₀ values were decreased by 52% (M c1, P=0.0002) and 42% (M c2, P=0.0015) in 2D culture model of MIA Paca-2 cells; (B) IC₅₀ values were decreased by 46% (P c1, P=0.0006) and 41% (P c2, P=0.0013) 2D model for PANC-1; (C) 3D model for MIA Paca-2; and (D) 3D model for PANC-1. Values are expressed as the mean and standard deviation (n=3). Solid lines are non-linear regression fits ($Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / [1 + 10^{(\text{LogIC}_{50} - X)}]$) to the data. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 according to Sidak's post-hoc tests that followed two-way ANOVA. Con., concentration.

is drug efflux via ABC transporters (44). Pancreatic cancer involves overexpression of numerous ABC transporter genes, such as *MRP1*, *MRP2*, *MRP3*, *MRP4*, *MRP5*, *MRP8* and *breast cancer resistance protein (BCRP)* (4,45-47). These ABC transporters may work individually or together, which makes their mechanism of action quite intricate. Overexpression of these ABC transporters has also been correlated with resistance to chemotherapy. Accumulating evidence has shown that overexpression of *MRP2*, *MRP3*, *MRP4* and *MRP5* may be related to MDR and cancer progression (4,6,16,19,26,45-47).

Typical substrates of *MRP5* include nucleotide analogues and gemcitabine is a nucleoside analogue. *In vitro* studies showed that *MRP5* contributes to resistance to gemcitabine and other nucleoside analog drugs in PDAC cell lines and 293 cells overexpressing *MRP5* (6,20,28,48). Exposure of PDAC cells to gemcitabine markedly increased *MRP5* levels, thus indicating a drug-induced resistance mechanism of PDAC cells (28,48). Previous studies have revealed that the use of *MRP5* inhibitor curcumin significantly enhanced cytotoxicity of gemcitabine on *MRP5*-overexpressing pancreatic cancer cells, which showed its reversal effect on MDR mediated by *MRP5* (32,49). On the other hand, however, one study reported that overexpression of *MRP4* and *MRP5* conferred resistance to cytarabine and troxacitabine, but not gemcitabine (50). Such discrepancy may be due to the differences in *MRP5* expression on the plasma membrane among different cell clones (11). Several studies examining the importance of other ABC transporters in gemcitabine resistance have confirmed that abnormal expression of P-glycoprotein, *MRP1*, *MRP4* and *BCRP* is associated with MDR in pancreatic cancer (51,52). Some research has shown that *MRP2* and *MRP4* may have

Table II. Gemcitabine-induced growth inhibition: Comparison between scramble control and multidrug resistance protein 5-short-hairpin RNA-transduced clones in 2D cultures.

A, MIA Paca-2		
Transduced cells	IC ₅₀ , nM	P-value
Scramble control	17.26±1.7	
M c1	8.31±0.82	0.0002
M c2	9.94±0.38	0.0015
B, PANC-1		
Transduced cells	IC ₅₀ , nM	P-value
Scramble control	13.88±1.84	
P c1	7.43±0.01	0.0006
P c2	8.23±1.14	0.0013

Values are expressed as the mean ± standard deviation of three independent experiments.

affinity for nucleotide analogues (6). Although *in vitro* evidence suggests that overexpression of ABC transporters confers resistance to cytotoxic and molecularly targeted chemotherapies, studies indicate that ABC transporters may also contribute to cancer development and metastasis independent of their efflux function (6,12,16,28,32,45). In the present




Figure 4. Representative gemcitabine-induced apoptosis in MIA PaCa-2 (A and B) and PANC-1 (C and D) clones transduced with scramble control and multi-drug resistance protein 5-short-hairpin RNA. MIA PaCa-2 and PANC-1 clones were treated with gemcitabine (100 and 200 nM) for 24 and 48 h, respectively. The apoptotic cells were stained with CellEvent™ Caspase-3/7 Green Detection Reagent and visualised by fluorescence microscopy (scale bars, 100 μ m). The fluorescence intensity was then measured using a plate reader. Data are presented as a mean percentage of vehicle control. The bars represent the mean and standard deviation from three independent experiments performed in triplicates. * P <0.05; ** P <0.01; *** P <0.001 according to Sidak's post-hoc test that followed two-way ANOVA. Con., concentration.




Figure 5. Representative clonogenic growth images of (A) MIA PaCa-2 and (B) PANC-1 clones transduced with scrambled control and multidrug resistance protein 5-short-hairpin RNA. MIA PaCa-2 and PANC-1 clones at a density of 200 cells/well were seeded into a 6-well plate and incubated for 10 days. Colonies of >50 cells were scored for survival and counted using ImageJ 1.52g software. The number of colonies formed by (C) MIA PaCa-2 and (D) PANC-1 cells is presented as a mean percentage of the scrambled control. The bars represent the mean and standard deviation from three independent experiments performed in duplicates. * P <0.05; *** P <0.001; **** P <0.0001 from Dunnett's post-hoc test that followed one-way ANOVA.

study, silencing *MRP5* by lentiviral shRNA was used to further clarify the contribution of *MRP5* to pancreatic cancer

proliferation, migration and gemcitabine cytotoxicity in Mia PaCa-2 and PANC-1 cells with endogenous *MRP5* expression.




Figure 6. Representative images for the wound-healing assay using (A) MIA Paca-2 and (B) PANC-1 clones transduced with scrambled control and multi-drug resistance protein 5-short-hairpin RNA. Quantified scratch wound coverage in (C) MIA Paca-2 and (D) PANC-1 cells. Images taken at the designated time-points (total magnification, x40) were analysed by ImageJ 1.52g software and data are presented as a mean percentage of the control (0 h). The bars represent the mean and standard deviation from three independent experiments performed in triplicates. * $P < 0.05$; ** $P < 0.01$; **** $P < 0.0001$ from Dunnett's post-hoc test that followed two-way ANOVA.




Figure 7. Representative Transwell migration images of (A) MIA Paca-2 and (B) PANC-1 clones transduced with scrambled control and multidrug resistance protein 5-short-hairpin RNA (scale bars, 200 μ m). Migrated cells were quantified as a mean percentage of scrambled control in (C) MIA Paca-2 and (D) PANC-1 cells. The bars represent the mean and standard deviation from three independent experiments performed in triplicates. *** $P < 0.001$; **** $P < 0.0001$ from Dunnett's post-hoc test that followed one-way ANOVA.

In the present study, *MRP5* gene knockdown in MIA Paca-2 and PANC-1 cells was confirmed on both the mRNA and protein levels. The *MRP5* mRNA transcripts and surface immunostaining were significantly lower in the shRNA lentiviral particles-transduced cells as compared to the scrambled control. *MRP5* has been demonstrated to confer gemcitabine resistance in various *in vitro* cell culture models (6,20,28,48). While the current study focused on the non-efflux function of

MRP5, the increased gemcitabine sensitivity may be used as additional evidence of *MRP5* silencing, in conjugation with the surface staining and RT-qPCR results.

The cytotoxicity assay demonstrated that gemcitabine sensitivity for the knockdown clones was increased by roughly 2-fold for both MIA PaCa-2 and PANC-1 cells. By contrast, the knockdown clones did not show increased vulnerability to olaparib, which is not an *MRP5* substrate. This supports the current




Figure 8. Ligands docked on MRP5 macromolecule. Binding of (A) gemcitabine and (B) cyclic guanosine monophosphate with MRP5. MRP5 is depicted in red colour in ribbon form. MRP5, multidrug resistance protein 5.

hypothesis that overexpression of MRP5 is one of the major reasons for gemcitabine resistance in pancreatic cancer cells. The effect of the *MRP5* knockdown on gemcitabine-induced apoptosis in pancreatic cancer cells was also tested. Silencing *MRP5* by shRNA resulted in an increase in gemcitabine-induced caspase3/7-mediated apoptosis in MIA Paca-2 and PANC-1 cells. Further studies are required to better understand the molecular mechanisms of the potential roles of MRP5 in the protection against apoptosis in pancreatic cancer cells.

The present results suggest that depletion of MRP5 significantly reduced the number of colonies formed and diminished cell mobility/migration in pancreatic cancer cells. A recent study indicates that downregulation of MRP5 and BCRP induced cell apoptosis and reduced the migration ability of colorectal cancer cells (53). Upregulation of MRP5 was associated with enhanced cell proliferation, migration and invasion of prostate cancer *in vitro* and *in vivo* (54). It was previously reported that MRP5 is a mediator of breast cancer skeletal metastasis and loss of MRP5 expression diminishes the formation of breast cancer bone metastases without promoting breast cancer proliferation (55). It was postulated that the locally elevated level of cGMP, which is pumped out by MRP5, can further increase osteoclast motility. The *in silico* analysis of the present study indicated high binding affinity of cGMP towards MRP5, which supports the role of MRP5 in the accumulation of cGMP in the microenvironment.

Whether pancreatic cancer cells that express MRP5, and thus maintain low cytoplasmic cGMP levels through active efflux, are associated with pancreatic cancer metastasis warrants further investigation.

Despite the coherence of the present results, there are several limitations to this study, including the low knockdown efficiency and potential off-target effects induced by shRNA-mediated gene silencing. More recently, the development of CRISPR inhibition and CRISPR activation has enabled researchers to explore the complex gene pathways associated with drug resistance and cancer hallmarks (56,57). Given the unique functionality of MRP5, such approaches would be applied to decipher the mechanism of actions of MRP5 and elucidate the regulatory pathways in pancreatic cancer. In addition, the present results were not validated in *in vivo* pancreatic cancer models, which offer complex biological systems and tumour microenvironment to evaluate cancer hallmarks and tumour resistance (58,59).

In conclusion, the present study adds to the growing body of evidence that MRP5 has an important role in cancer proliferation and migration independent of its drug efflux functions. Gemcitabine-based chemotherapy has been widely adopted as the standard and preferred chemotherapy regimen for treating advanced pancreatic cancer. Pancreatic cancer is highly metastatic and resistant to multiple drugs, including the front-line drug gemcitabine. The current results showed that MRP5 (ABCC5) confers gemcitabine resistance and promotes

pancreatic cancer cell proliferation and migration, and modulation of MRP5 may reverse its protumour effect and enhance gemcitabine sensitivity. Therefore, it may be proposed that modulating MRP5 transporter activity or its regulatory pathways may be a potential therapeutic strategy in patients with high expression levels of MRP5.

Acknowledgements

Not applicable.

Funding

This research was funded by the Faculty of Health and Environmental Science (Auckland University of Technology, NZ) Research and Development Fund 2022.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

Conceptualization, ZW and YL; methodology, JH, PB, JL, RB, SL, XY, FT and YL; software, JH, PB, JL, RB, SL and FT; validation, JH, PB, JL, RB and SL; formal analysis, JH and YL; investigation, JH, PB, JL, RB and SL; resources, YL; data curation, JH; writing - original draft preparation, JH and PB; writing - review and editing, JH, PB, JL, XY, FT, ZW and YL; visualization, JH and JL; supervision, YL; project administration, ZW and YL; funding acquisition, YL. JH and YL confirm the authenticity of all the raw data. All authors have read and agreed to the published version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Adamska A, Domenichini A and Falasca M: Pancreatic ductal adenocarcinoma: Current and evolving therapies. *Int J Mol Sci* 18: 1338, 2017.
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjuland SA, Ma WW, Saleh MN, *et al*: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 369: 1691-1703, 2013.
- Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécauarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, *et al*: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 364: 1817-1825, 2011.
- Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V, Chiorino G, Akkaya BG, Linton KJ, De Laurenzi V, *et al*: ABCC3 is a novel target for the treatment of pancreatic cancer. *Adv Biol Regul* 73: 100634, 2019.
- Gnanamony M and Gondi CS: Chemoresistance in pancreatic cancer: Emerging concepts. *Oncol Lett* 13: 2507-2513, 2017.
- Adamska A and Falasca M: ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? *World J Gastroenterol* 24: 3222-3238, 2018.
- Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. *FEBS Lett* 580: 2903-2909, 2006.
- O'Reilly EM: Pancreatic adenocarcinoma: New strategies for success. *Gastrointest Cancer Res* 3: S11-S15, 2009.
- Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. *Lancet* 378: 607-620, 2011.
- Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. *Nat Rev Drug Discov* 5: 219-234, 2006.
- Borst P, de Wolf C and van de Wetering K: Multidrug resistance-associated proteins 3, 4, and 5. *Pflugers Arch* 453: 661-673, 2007.
- Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE and Gottesman MM: Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat Rev Cancer* 18: 452-464, 2018.
- Dvorak P, Pesta M and Soucek P: ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer. *Tumour Biol* 39: 1010428317699800, 2017.
- Sodani K, Patel A, Kathawala RJ and Chen ZS: Multidrug resistance associated proteins in multidrug resistance. *Chin J Cancer* 31: 58-72, 2012.
- Tiwari AK, Sodani K, Dai CL, Ashby CR Jr and Chen ZS: Revisiting the ABCs of multidrug resistance in cancer chemotherapy. *Curr Pharm Biotechnol* 12: 570-594, 2011.
- Bugde P, Biswas R, Merien F, Lu J, Liu DX, Chen M, Zhou S and Li Y: The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. *Expert Opin Ther Targets* 21: 511-530, 2017.
- Fukuda Y and Schuetz JD: ABC transporters and their role in nucleoside and nucleotide drug resistance. *Biochem Pharmacol* 83: 1073-1083, 2012.
- Vasilou V, Vasilou K and Nebert DW: Human ATP-binding cassette (ABC) transporter family. *Hum Genomics* 3: 281-290, 2009.
- Choi YH and Yu AM: ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. *Curr Pharm Des* 20: 793-807, 2014.
- Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J and Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. *Mol Pharmacol* 63: 1094-1103, 2003.
- König J, Hartel M, Nies AT, Martignoni ME, Guo J, Büchler MW, Friess H and Keppler D: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. *Int J Cancer* 115: 359-367, 2005.
- Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Böhm M, Warzok R, Kerb R, Brinkmann U, Schaeffeler E, *et al*: Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. *Am J Pathol* 163: 1567-1577, 2003.
- Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova E, Kala Z, Muckova K and Soucek P: Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. *Pancreas* 42: 707-716, 2013.
- Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. *Cancer Lett* 370: 153-164, 2016.
- Slot AJ, Molinski SV and Cole SP: Mammalian multidrug-resistance proteins (MRPs). *Essays Biochem* 50: 179-207, 2011.
- Zeng S, Pottler M, Lan B, Grützmann R, Pilarsky C and Yang H: Chemoresistance in pancreatic cancer. *Int J Mol Sci* 20: 4504, 2019.
- Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL and Li D: Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. *Cancer* 117: 744-751, 2011.
- Hagmann W, Faissner R, Schnolzer M, Löhr M and Jesnowski R: Membrane drug transporters and chemoresistance in human pancreatic carcinoma. *Cancers (Basel)* 3: 106-125, 2010.
- Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M, Muramatsu H, Maeda H, Niimi T and Ueda R: The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: A role of ABCC5 in gemcitabine sensitivity. *Mol Cancer Ther* 5: 1800-1806, 2006.

30. Fletcher JI, Haber M, Henderson MJ and Norris MD: ABC transporters in cancer: More than just drug efflux pumps. *Nat Rev Cancer* 10: 147-156, 2010.
31. Domenichini A, Adamska A and Falasca M: ABC transporters as cancer drivers: Potential functions in cancer development. *Biochim Biophys Acta Gen Subj* 1863: 52-60, 2019.
32. He J, Fortunati E, Liu DX and Li Y: Pleiotropic roles of ABC transporters in breast cancer. *Int J Mol Sci* 22: 3199, 2021.
33. Calcagno AM and Ambudkar SV: Analysis of expression of drug resistance-linked ABC transporters in cancer cells by quantitative RT-PCR. *Methods Mol Biol* 637: 121-132, 2010.
34. Li C, Chen D, Luo M, Ge M and Zhu J: Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo. *Biotechnol J* 9: 652-663, 2014.
35. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
36. Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. *Nat Protoc* 2: 329-333, 2007.
37. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Židek A, Potapenko A, *et al*: Highly accurate protein structure prediction with AlphaFold. *Nature* 596: 583-589, 2021.
38. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, *et al*: AlphaFold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res* 50: D439-D444, 2022.
39. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T and Hutchison GR: Open babel: An open chemical toolbox. *J Cheminform* 3: 33, 2011.
40. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS and Olson AJ: AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* 30: 2785-2791, 2009.
41. Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ and Schroeder M: PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA. *Nucleic Acids Res* 49: W530-W534, 2021.
42. Schoning-Stierand K, Diedrich K, Fahrrolfes R, Flachsenberg F, Meyder A, Nittinger E, Steinegger R and Rarey M: ProteinsPlus: Interactive analysis of protein-ligand binding interfaces. *Nucleic Acids Res* 48: W48-W53, 2020.
43. Laskowski RA and Swindells MB: LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model* 51: 2778-2786, 2011.
44. Kohan HG and Boroujerdi M: Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells. *Xenobiotica* 45: 642-652, 2015.
45. Amponsah PS, Fan P, Bauer N, Zhao Z, Gladkich J, Fellenberg J and Herr I: microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. *Cancer Lett* 388: 107-117, 2017.
46. Kriebel PW, Majumdar R, Jenkins LM, Senoo H, Wang W, Ammu S, Chen S, Narayan K, Iijima M and Parent CA: Extracellular vesicles direct migration by synthesizing and releasing chemotactic signals. *J Cell Biol* 217: 2891-2910, 2018.
47. Biswas R, Bugde P, He J, Merien F, Lu J, Liu DX, Myint K, Liu J, McKeage M and Li Y: Transport-mediated oxaliplatin resistance associated with endogenous overexpression of MRP2 in Caco-2 and PANC-1 cells. *Cancers (Basel)* 11: 1330, 2019.
48. Nambaru PK, Hubner T, Kock K, Mews S, Grube M, Payen L, Guittion J, Sendler M, Jedlitschky G, Rimbach C, *et al*: Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anti-cancer drug 5-fluorouracil. *Drug Metab Dispos* 39: 132-139, 2011.
49. Yoshida K, Toden S, Ravindranathan P, Han H and Goel A: Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. *Carcinogenesis* 38: 1036-1046, 2017.
50. Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G and Peters GJ: Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. *Springerplus* 3: 732, 2014.
51. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL and Peters GJ: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. *Br J Cancer* 88: 1963-1970, 2003.
52. Polgar O and Bates SE: ABC transporters in the balance: Is there a role in multidrug resistance? *Biochem Soc Trans* 33: 241-245, 2005.
53. El-Daly SM, Abo-Elfadl MT, Hussein J and Abo-Zeid MAM: Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. *Life Sci* 315: 121320, 2023.
54. Ji G, He S, Huang C, Gong Y, Li X and Zhou L: Upregulation of ATP binding cassette subfamily c member 5 facilitates prostate cancer progression and enzalutamide resistance via the CDK1-mediated AR Ser81 phosphorylation pathway. *Int J Biol Sci* 17: 1613-1628, 2021.
55. Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, *et al*: ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. *Breast Cancer Res* 14: R149, 2012.
56. Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Bueno R, Nguyen VQ, Blaeschke F, Ye CJ and Marson A: CRISPR activation and interference screens decode stimulation responses in primary human T cells. *Science* 375: eabj4008, 2022.
57. Morelli E, Gulla A, Amodio N, Taiana E, Neri A, Fulciniti M and Munshi NC: CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to explore the Oncogenic lncRNA network. *Methods Mol Biol* 2348: 189-204, 2021.
58. Borst P: Looking back at multidrug resistance (MDR) research and ten mistakes to be avoided when writing about ABC transporters in MDR. *FEBS Lett* 594: 4001-4011, 2020.
59. Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E, Wang Y, Lin R, Wang H, Liu Z, *et al*: Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. *Drug Resist Updat* 68: 100960, 2023.



Copyright © 2023 He et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.